Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells

MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways

(2015) Anne Y. Saiki et al.   Oncotarget

Targeting Class IA PI3K Isoforms Selectively Impairs Cell Growth, Survival, and Migration in Glioblastoma

(2014) Katrin Höland et al.   PLoS One

Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy

(2014) S Daniele et al.   Cell Death & Disease

Apoptosis Therapy in Cancer: The First Single-molecule Co-activating p53 and the Translocator Protein in Glioblastoma

(2014) Simona Daniele et al.   Scientific Reports

KML001, a Telomere-Targeting Drug, Sensitizes Glioblastoma Cells to Temozolomide Chemotherapy and Radiotherapy through DNA Damage and Apoptosis

(2014) Seon Rang Woo et al.   Biomed Research International

mTOR signaling and its roles in normal and abnormal brain development

(2014) Nobuyuki Takei et al.   Frontiers in Molecular Neuroscience

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

(2013) Howard A. Burris   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Targeting Cancer Stem Cells for Treatment of Glioblastoma Multiforme

(2013) Der-Yang Cho et al.   CELL TRANSPLANTATION

Efficacy of rapamycin against glioblastoma cancer stem cells

(2013) M. Mendiburu-Eliçabe et al.   Clinical & Translational Oncology

Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma

(2013) Meenakshi Hegde et al.   MOLECULAR THERAPY

Human Glioblastoma Multiforme: p53 Reactivation by a Novel MDM2 Inhibitor

(2013) Barbara Costa et al.   PLoS One

Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme

(2013) Bryant England et al.   TUMOR BIOLOGY

Synthesis of Novel 3,5-Disubstituted-2-oxindole Derivatives As Antitumor Agents against Human Nonsmall Cell Lung Cancer

(2013) Giulia Nesi et al.   ACS Medicinal Chemistry Letters

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

(2012) Isabelle Ray-Coquard et al.   LANCET ONCOLOGY

Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program

(2012) Hernan Carol et al.   PEDIATRIC BLOOD & CANCER

Everolimus: Targeted Therapy on the Horizon for the Treatment of Breast Cancer

(2012) Chad M. Barnett   PHARMACOTHERAPY

Induction of autophagy promotes differentiation of glioma-initiating cells and their radiosensitivity

(2011) Wenzhuo Zhuang et al.   INTERNATIONAL JOURNAL OF CANCER

Activation of p53 by Nutlin-3a Induces Apoptosis and Cellular Senescence in Human Glioblastoma Multiforme

(2011) Ruth Villalonga-Planells et al.   PLoS One

MEK-ERK Signaling Dictates DNA-Repair Gene MGMT Expression and Temozolomide Resistance of Stem-Like Glioblastoma Cells via the MDM2-p53 Axis

(2011) Atsushi Sato et al.   STEM CELLS

The therapeutic promise of the cancer stem cell concept

(2010) Natasha Y. Frank et al.   JOURNAL OF CLINICAL INVESTIGATION

Identification of the Spiro(oxindole-3,3′-thiazolidine)-Based Derivatives as Potential p53 Activity Modulators

(2010) Isabel Gomez-Monterrey et al.   JOURNAL OF MEDICINAL CHEMISTRY

Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells

(2010) Jun Sunayama et al.   NEURO-ONCOLOGY

Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self-Renewal and Tumorigenicity of Glioblastoma Stem-Like Cells

(2010) Jun Sunayama et al.   STEM CELLS

Dissecting the role of mTOR: Lessons from mTOR inhibitors

(2009) Ryan J.O. Dowling et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy

(2009) RuiRong Yuan et al.   Journal of Hematology & Oncology

The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML

(2008) K Kojima et al.   LEUKEMIA

Activation of p53 by nutlin leads to rapid differentiation of human embryonic stem cells

(2008) T Maimets et al.   ONCOGENE